419 Shares in Revvity Inc. (NYSE:RVTY) Acquired by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC purchased a new position in Revvity Inc. (NYSE:RVTY) during the first quarter, Holdings Channel.com reports. The fund purchased 419 shares of the company’s stock, valued at approximately $44,000.

Other hedge funds also recently modified their holdings of the company. Optiver Holding B.V. bought a new stake in shares of Revvity in the 4th quarter worth approximately $33,000. Quarry LP raised its holdings in Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company’s stock valued at $34,000 after acquiring an additional 95 shares during the period. Vermillion Wealth Management Inc. bought a new stake in Revvity during the 4th quarter valued at $41,000. Continuum Advisory LLC raised its holdings in Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company’s stock valued at $53,000 after acquiring an additional 133 shares during the period. Finally, GeoWealth Management LLC bought a new stake in Revvity during the 4th quarter valued at $60,000. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

NYSE RVTY opened at $85.82 on Tuesday. The company has a 50-day simple moving average of $95.07 and a two-hundred day simple moving average of $100.84. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43. Revvity Inc. has a 12-month low of $85.12 and a 12-month high of $129.50. The firm has a market cap of $9.96 billion, a price-to-earnings ratio of 36.36, a PEG ratio of 2.33 and a beta of 0.91.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The business had revenue of $720.28 million during the quarter, compared to analyst estimates of $711.26 million. During the same period in the prior year, the business posted $1.22 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. On average, equities analysts forecast that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity’s dividend payout ratio is presently 11.86%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Bank of America decreased their price target on shares of Revvity from $116.00 to $110.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Stifel Nicolaus decreased their price target on shares of Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a report on Tuesday, July 29th. Wells Fargo & Company decreased their price target on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Robert W. Baird decreased their price target on shares of Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, April 29th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $115.00 price target (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $120.07.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.